CAL
ALNY icon

Capital Analysts LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

Capital Analysts LLC’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$1K – 1296
2024
Q3 		$1K Buy
+2
New +$521 ﹤0.01% 1237

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Capital Analysts LLC's ALNY Position: Q4 2024 in Review

Capital Analysts LLC sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 2 shares — an estimated $1K sold.

Capital Analysts LLC first reported a position in ALNY in Q3 2024 and held it in 1 quarter. The position peaked at $1K in Q3 2024. 595 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

  • Capital Analysts LLC reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Analysts LLC sold 2 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $1K.
  • Capital Analysts LLC first reported a position in Alnylam Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Analysts LLC's Alnylam Pharmaceuticals position peaked at $1K in Q3 2024.
  • 595 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on Capital Analysts LLC's 13F filing for Q4 2024, filed 14 Feb 2025.